| 000 | 01788 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250513195202.0 | ||
| 264 | 0 | _c19991216 | |
| 008 | 199912s 0 0 eng d | ||
| 022 | _a1043-0342 | ||
| 024 | 7 |
_a10.1089/10430349950016726 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWildner, O | |
| 245 | 0 | 0 |
_aSynergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan. _h[electronic resource] |
| 260 |
_bHuman gene therapy _cNov 1999 |
||
| 300 |
_a2679-87 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_aAdenoviridae _xgenetics |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 |
_aAntiviral Agents _xpharmacology |
| 650 | 0 | 4 | _aCarcinogenicity Tests |
| 650 | 0 | 4 |
_aCarcinoma _xdrug therapy |
| 650 | 0 | 4 |
_aColonic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGanciclovir _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred BALB C |
| 650 | 0 | 4 | _aMice, Inbred C57BL |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 |
_aProdrugs _xadministration & dosage |
| 650 | 0 | 4 |
_aSimplexvirus _xenzymology |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aThymidine Kinase _xgenetics |
| 650 | 0 | 4 | _aTopoisomerase I Inhibitors |
| 650 | 0 | 4 |
_aTopotecan _xadministration & dosage |
| 650 | 0 | 4 | _aTransplantation, Heterologous |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 700 | 1 | _aBlaese, R M | |
| 700 | 1 | _aMorris, J C | |
| 773 | 0 |
_tHuman gene therapy _gvol. 10 _gno. 16 _gp. 2679-87 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1089/10430349950016726 _zAvailable from publisher's website |
| 999 |
_c10523178 _d10523178 |
||